UNAIDS estimated that there were some ******* people worldwide that died from acquired immune deficiency syndrome (AIDS) in 2024. This statistic depicts the total number of annual AIDS-related deaths worldwide from 2000 to 2024. HIV/AIDS burden A majority of countries with the highest burden due to HIV and AIDS are in Africa- in 2024, the highest number of AIDS-related deaths occurred in South Africa and Mozambique and the highest prevalence of HIV was found in Eswatini. Although access to life-saving antiretroviral therapy treatment (ART) has increased globally over recent years, many individuals living with HIV still lack access to ART. Barriers and interventions In part due to the development of ART, the number of people living with HIV worldwide is continuing to increase, reaching almost ** million in 2024. Important public health measures to combat the burden of the disease include a combination of biomedical and behavioral interventions such as pre- and post-exposure prophylaxis, and context-specific structural interventions to reduce barriers to supplies and education. One prominent barrier faced by those living with HIV is stigma, which can often cause disadvantages in many areas of life, including employment, use of health services, and social support.

In 2024, South Africa and Mozambique had the highest number of deaths due to AIDS worldwide, with around ** thousand and ** thousand such deaths, respectively. African countries account for eight of the top 10 countries with the highest number of AIDS-related deaths worldwide. AIDS-related deaths worldwide have been gradually declining over the past decade, decreasing from *** million deaths in 2010 to *** thousand deaths in 2024. HIV/AIDS HIV (human immunodeficiency virus) is an infectious sexually transmitted disease that is transmitted via exposure to infected semen, blood, vaginal and anal fluids and breast milk. HIV weakens the human immune system, resulting in the affected person being unable to fight off opportunistic infections. The top 15 countries worldwide with the highest prevalence of new HIV infections as of 2024 were all African. HIV treatment Although there is currently no effective cure for HIV, death can be prevented by taking HIV antiretroviral therapy (ART). Access to antiretroviral therapy worldwide has significantly increased in the past decade. As of 2024, around **** million people with HIV worldwide were receiving ART. The countries with the highest percentage of HIV-infected children who were receiving ART were Eswatini, Kenya, and Lesotho.

In January 2025, President Trump ordered a pause on funding for the U.S. Agency for International Development (USAID) and a 90-day review of all U.S. foreign assistance. By the end of March, the review had been completed, 83 percent of USAID programs were terminated, and it was announced that certain USAID functions would be overtaken by the Department of State while all others would be discontinued. A preprint research paper posted in April 2025 looked at the possible effects that reductions or cessation of U.S. foreign aid would have on global health. The researchers estimated that the elimination of U.S. foreign aid for global health would result in an additional 15.2 million AIDS-related deaths from 2025 to 2040. Furthermore, they estimated that the loss of U.S. aid would lead to 26.2 million additional HIV infections over this period. This paper has not been peer-reviewed so the estimates should be interpreted with caution, but there is no doubt that such cuts to U.S. foreign aid will result in an increase in HIV infections and deaths, especially in high-impact countries. Trump has said that the United States spends too much on foreign aid and accused USAID of being corrupt and a waste of money. However, foreign aid accounts for just one percent of the federal budget. Furthermore, it is predicted that millions of people will die due to the dissolution of USAID, as vulnerable people around the world will no longer be able to access prevention and treatment for diseases such as HIV/AIDS, tuberculosis, and malaria.

this graph was created in Tableu and Ourdataworld :

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fc5bb0b21c8b3a126eca89160e1d25d03%2Fgraph1.png?generation=1710708871099084&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Ff81fcfa72e97f08202ba1cb06fe138da%2Fgraph2.png?generation=1710708877558039&alt=media" alt="">

https://www.googleapis.com/download/storage/v1/b/kaggle-user-content/o/inbox%2F16731800%2Fabbdfd146844a7e8d19e277c2eecb83b%2Fgraph3.png?generation=1710708883608541&alt=media" alt="">

Understanding the Global Distribution of HIV/AIDS Deaths

Introduction:

HIV/AIDS remains one of the most significant public health challenges globally, with its impact varying widely across countries and regions. While the overall share of deaths attributed to HIV/AIDS stands at around 1.5% globally, this statistic belies the stark disparities observed on a country-by-country basis. This essay delves into the global distribution of deaths from HIV/AIDS, examining both the overarching trends and the localized impacts across different regions, particularly focusing on Southern Sub-Saharan Africa.

Understanding Global Trends:

At a global level, HIV/AIDS accounts for approximately 1.5% of all deaths. This figure, though relatively low in comparison to other causes of mortality, represents a significant burden on public health systems and communities worldwide. However, when zooming in on specific regions, such as Europe, the share of deaths attributable to HIV/AIDS drops significantly, often comprising less than 0.1% of total mortality. This pattern suggests varying levels of prevalence and effectiveness of HIV/AIDS prevention and treatment strategies across different parts of the world.

Regional Disparities:

The distribution of HIV/AIDS deaths is not uniform across the globe, with certain regions experiencing disproportionately high burdens. Southern Sub-Saharan Africa emerges as a focal point of the HIV/AIDS epidemic, with a significant portion of deaths attributed to the virus occurring in this region. Factors such as limited access to healthcare, socio-economic disparities, cultural stigmatization, and insufficient education about HIV/AIDS contribute to the heightened prevalence and impact of the disease in this area.

Southern Sub-Saharan Africa: A Hotspot for HIV/AIDS Deaths:

Within Southern Sub-Saharan Africa, countries such as South Africa, Botswana, and Swaziland stand out for their exceptionally high rates of HIV/AIDS-related mortality. In these nations, HIV/AIDS can account for up to a quarter of all deaths, highlighting the acute nature of the epidemic in these regions. The reasons behind this disproportionate burden are multifaceted, encompassing issues ranging from inadequate healthcare infrastructure to socio-cultural barriers inhibiting prevention and treatment efforts.

Challenges and Responses:

Addressing the unequal distribution of HIV/AIDS deaths necessitates a multi-faceted approach that encompasses both prevention and treatment strategies tailored to the specific needs of affected communities. Efforts to expand access to antiretroviral therapy (ART), promote comprehensive sexual education, combat stigma, and strengthen healthcare systems are crucial components of an effective response. Moreover, fostering partnerships between governments, civil society organizations, and international entities is essential for coordinating resources and expertise to tackle the HIV/AIDS epidemic comprehensively.

Lessons Learned and Future Directions:

The global distribution of deaths from HIV/AIDS underscores the importance of context-specific interventions that take into account the unique social, economic, and cultural factors influencing the spread and impact of the disease. While progress has been made in reducing HIV/AIDS-related mortality in some regions, much work remains to be done, particularly in areas where the burden of the epidemic remains disproportionately high. Going forward, sustained investment in research, healthcare infrastructure, and community empowerment initiatives will be vital for achieving meaningful reductions in HIV/AIDS deaths worldwide.

Conclusion:

In conclusion, the global distribution of deaths from HIV/AIDS reveals a complex landscape characterized by both overarching trends and localized disparities. While the overall share of deaths attributable to HIV/AIDS may seem relatively modest on a global scale, the stark contrasts observed across different countries and regions underscore the need for targeted interventions tailored to the specific contexts in which the epidemic is most pronounced. By addressing the underlying social, economic, and healthcare-related factors driving the unequal distribution of HIV/AIDS deaths, the global co...

HIV/AIDS deaths in the U.S. have dropped significantly in recent years. In 1995, the death rate from HIV per 100,000 people was ****. That number has since decreased to *** per 100,000 as of 2023. The reduction in the HIV death rate in the U.S. can be attributed to an increase in access to HIV medications. HIV/AIDS in the U.S. Human immunodeficiency virus (HIV) and acquired immune deficiency syndrome (AIDS) cause a systemic viral infection that damages the immune system. AIDS is a syndrome that is caused by HIV. AIDS is when the immune system is severely weakened by HIV and the body can no longer fight off infections. Among all U.S. states, Georgia, followed by Florida and Louisiana, had the highest rates of new HIV diagnoses in 2022. HIV/AIDS treatments in the U.S. HIV/AIDS treatments include antiretroviral medications to reduce the levels of HIV within the body. The largest funders for HIV/AIDS medications and research are the National Institutes of Health (NIH) and the Ryan White Program. The top HIV drug worldwide, based on revenue generated in 2023 was Biktarvy. Around the world, access to antiretroviral treatment has increased dramatically in recent years, a huge step in reducing the number of HIV-related deaths. There is currently no cure for HIV.

Introduction

• HIV (human immunodeficiency virus) is a virus that attacks the body's immune system. If HIV is not treated, it can lead to AIDS (acquired immunodeficiency syndrome) which currently has no cure. Once people get HIV, they have it for life. But with proper medical care, HIV can be controlled. Symptoms: Influenza-like illness; Fatigue… Treatments: Management of HIV/AIDS Type of infectious agent: Virus (Human Immunodeficiency Virus) • AIDS (acquired immune deficiency syndrome) is the name used to describe a number of potentially life-threatening infections and illnesses that happen when one’s immune system has been severely damaged by the HIV virus. While AIDS cannot be transmitted from 1 person to another, the HIV virus can.

Dataset

The data set contains data of the following:- 1. The top causes of deaths in the world 2. Total number of deaths due to HIV/AIDS 3. ART (Anti Retro-viral Therapy) coverage among people living with HIV 4. Knowledge among young citizens (15-24years) about HIV/AIDS 5. Population of HIV/AIDS patients living with TB and their death rate 6. Life expectancy rate among HIV/AIDS patients 7. HIV/AIDS Patients in different age groups 8. Women population living with HIV 9. Young women in India having the knowledge of HIV/AIDS 10. HIV/AIDS deaths in Indian states

Data was scrapped from the official website of UNICEF -https://data.unicef.org/ and https://data.gov.in/

Ask Phase

• Data gives the trend of increasing no. of HIV/AIDS patients across the world • The information available for each country is percentage of total Global AIDS patients • Time period traced is 2000-2019 • Key Questions to answer:  Which countries and regions are affected the most?  How are the different age groups affected?  How much is the ART (Anti Retro-viral Therapy) coverage among the patients and what is the life expectancy rate?  What percentage of the population is aware of the prevention and causes of HIV/AIDS

Prepare phase.

• By tabulating and filtering the data the required data was obtained to bring out observations. • Data was formatted to the desired format to perform further calculations. • Sorting of data region wise. • Columns with inconsistent and empty cells were deleted. • The data of India was extracted for further analysis • Duplicate entries and undesired data was removed

Process phase

For cleaning the dataset for further analysis MS Excel was used due to small data. • Used sumifs() functions to aggregate the data region wise • Used sumif() to segregate the no. of patients within different age groups • Used sumifs() to find the total number of TB patients among HIV deaths. • Used countif() to find the percentage of male and female patients. • Sorted data to find the top and bottom nation with most and least HIV/AIDS patients

Analyze phase

• Formed the following pivot tables to answer key target questions  Year v/s number of death rates  Country v/s death numbers to bring out nation wise deaths  Causes of death v/s the number of deaths to bring at which position AIDS causes causality  Year v/s percentage of life expectancy to observe the pattern of no. of survivors

Visualization phase

The data was visualized using Tableau.

Presentaion

The final presentation was prepared by accumulating all observations and inferences which is linked below https://docs.google.com/presentation/d/1NEX10Vz5u5Va3CrTLVbvsUHZjO-fn8EOeiOHkP03T3Q/edit?usp=sharing

Between 2010 and 2024, Eastern Europe and Central Asia was the only region to see an increase in the number of AIDS-related deaths worldwide, with the annual figure increasing by ** percent. Meanwhile, the annual number of AIDS-related deaths declined by 54 percent globally in the same period, with the region of the Caribbean achieving the highest decrease with ** percent.

In 2023, South Africa had the highest number of adult AIDS-related deaths in the world at 49,000 deaths among adults aged 15 years and older. However, Mozambique had the highest number of child AIDS-related deaths worldwide. This statistic presents the number of AIDS-related deaths among adults in select African countries in 2023.

In 2023, Nigeria had the highest number of child AIDS-related deaths in the world, at around 15,000 deaths. It was also the country with the second-highest number of deaths due to AIDS worldwide. This statistic presents the number of AIDS-related deaths among children aged 0 to14 years in select African countries in 2023.

BackgroundThrough major efforts to reduce costs and expand access to antiretroviral therapy worldwide, widespread delivery of effective treatment to people living with HIV/AIDS is now conceivable even in severely resource-constrained settings. However, the potential epidemiologic impact of treatment in the context of a broader strategy for HIV/AIDS control has not yet been examined. In this paper, we quantify the opportunities and potential risks of large-scale treatment roll-out. Methods and FindingsWe used an epidemiologic model of HIV/AIDS, calibrated to sub-Saharan Africa, to investigate a range of possible positive and negative health outcomes under alternative scenarios that reflect varying implementation of prevention and treatment. In baseline projections, reflecting “business as usual,” the numbers of new infections and AIDS deaths are expected to continue rising. In two scenarios representing treatment-centered strategies, with different assumptions about the impact of treatment on transmissibility and behavior, the change in the total number of new infections through 2020 ranges from a 10% increase to a 6% reduction, while the number of AIDS deaths through 2020 declines by 9% to 13%. A prevention-centered strategy provides greater reductions in incidence (36%) and mortality reductions similar to those of the treatment-centered scenarios by 2020, but more modest mortality benefits over the next 5 to 10 years. If treatment enhances prevention in a combined response, the expected benefits are substantial—29 million averted infections (55%) and 10 million averted deaths (27%) through the year 2020. However, if a narrow focus on treatment scale-up leads to reduced effectiveness of prevention efforts, the benefits of a combined response are considerably smaller—9 million averted infections (17%) and 6 million averted deaths (16%). Combining treatment with effective prevention efforts could reduce the resource needs for treatment dramatically in the long term. In the various scenarios the numbers of people being treated in 2020 ranges from 9.2 million in a treatment-only scenario with mixed effects, to 4.2 million in a combined response scenario with positive treatment–prevention synergies. ConclusionsThese analyses demonstrate the importance of integrating expanded care activities with prevention activities if there are to be long-term reductions in the number of new HIV infections and significant declines in AIDS mortality. Treatment can enable more effective prevention, and prevention makes treatment affordable. Sustained progress in the global fight against HIV/AIDS will be attained only through a comprehensive response.

As of 2024, South Africa was the country with the highest number of people living with HIV in Africa. At that time, around 7.8 million people in South Africa were HIV positive. In Mozambique, the country with the second-highest number of HIV-positive people in Africa, around 2.5 million people were living with HIV. Which country in Africa has the highest prevalence of HIV? Although South Africa has the highest total number of people living with HIV in Africa, it does not have the highest prevalence of HIV on the continent. Eswatini currently has the highest prevalence of HIV in Africa and worldwide, with almost 26 percent of the population living with HIV. South Africa has the third-highest prevalence, with around 18 percent of the population HIV positive. Eswatini also has the highest rate of new HIV infections per 1,000 population worldwide, followed by South Africa and Mozambique. However, South Africa had the highest total number of new HIV infections in 2024, with around 170,000 people newly infected with HIV that year. Deaths from HIV in Africa Thanks to advances in treatment and awareness, HIV/AIDS no longer contributes to a significant amount of death in many countries. However, the disease is still the eighth leading cause of death in Africa, accounting for around 4.6 percent of all deaths. In 2024, South Africa and Mozambique were the countries with the highest number of AIDS-related deaths worldwide, with 53,000 and 44,000 such deaths, respectively. Although not every country in the leading 25 for AIDS-related deaths is found in Africa, African countries account for the majority of countries on the list. Fortunately, HIV treatment has become more accessible in Africa over the years, and now up to 94 percent of people living with HIV in Eswatini are receiving antiretroviral therapy (ART). Access to ART does vary from country to country, however, with around 81 percent of people who are HIV positive in South Africa receiving ART and only 34 percent in the Congo.

Description:

This dataset explores the factors influencing life expectancy across various countries and years, aiming to uncover patterns and disparities in health outcomes based on geographic locations. By examining key features such as adult mortality, alcohol consumption, healthcare expenditures, and socioeconomic indicators, this dataset provides insights into the complex interplay of factors shaping life expectancy worldwide.

Feature Description:

Source:

World Health Organization (WHO), United Nations (UN), World Bank, etc.

Sub-Saharan Africa represents 69% of the total number of individuals living with HIV infection worldwide and 72% of AIDS deaths globally. Pulmonary infection is a common and frequently fatal complication, though little is known regarding the lower airway microbiome composition of this population. Our objectives were to characterize the lower airway microbiome of Ugandan HIV-infected patients with pneumonia, to determine relationships with demographic, clinical, immunological, and microbiological variables and to compare the composition and predicted metagenome of these communities to a comparable cohort of patients in the US (San Francisco). Bronchoalveolar lavage samples from a cohort of 60 Ugandan HIV-infected patients with acute pneumonia were collected. Amplified 16S ribosomal RNA was profiled and aforementioned relationships examined. Ugandan airway microbiome composition and predicted metagenomic function were compared to US HIV-infected pneumonia patients. Among the most common bacterial pulmonary pathogens, Pseudomonas aeruginosa was most prevalent in the Ugandan cohort. Patients with a richer and more diverse airway microbiome exhibited lower bacterial burden, enrichment of members of the Lachnospiraceae and sulfur-reducing bacteria and reduced expression of TNF-alpha and matrix metalloproteinase-9. Compared to San Franciscan patients, Ugandan airway microbiome was significantly richer, and compositionally distinct with predicted metagenomes that encoded a multitude of distinct pathogenic pathways e.g secretion systems. Ugandan pneumonia-associated airway microbiome is compositionally and functionally distinct from those detected in comparable patients in developed countries, a feature which may contribute to adverse outcomes in this population.

In 2023, there were around 291 thousand deaths due to tuberculosis among HIV-negative people in Africa. In addition, there were 112 thousand deaths due to tuberculosis in Africa among people who were HIV-positive. This statistic shows the number of tuberculosis deaths worldwide in 2023, by region and HIV status.

Countries worldwide have attempted to reduce the incidence of HIV and AIDS associated deaths with varying success, despite significant progress in antiretroviral treatment (ART) and condom use. A chief obstacles is that key populations affected face high levels of stigma, discrimination and exclusion, limiting the successful response to HIV. However, a gap exists in studies demonstrating the moderation effects of societal enablers on overall programme effectiveness and HIV outcomes using quantitative methods.Structural Equation Modeling was used for 138 countries covering a 12-year period to examine how the unfavorable societal enabling environment, including stigma and discrimination, unfavorable legal environment and lack of access to societal justice, gender inequality and other unfavorable development situations affect the effectiveness of HIV programmes and HIV outcomes, while controlling for potentially confounding variables. The results only showed statistical significance when all four societal enablers were modeled as a composite. The findings show the direct and indirect standardized effects of unfavorable societal enabling environments to AIDS-related mortality among PLHIV are statistically significant and positive (0.26 and 0.08, respectively). We hypothesize that this may be because an unfavorable societal enabling environment can negatively affect adherence to ART, quality of healthcare and health seeking behavior. Higher ranked societal environments increase the effect of ART coverage on AIDS related mortality by about 50% in absolute value, that is -0.61 as against -0.39 for lower ranked societal environments. However, mixed results were obtained on the impact of societal enablers on changes in HIV incidence through condom use. Results indicate that countries with better societal enabling environments had fewer estimated new HIV infections and fewer AIDS-related deaths. The failure to include societal enabling environments in HIV response undermines efforts to achieve the 2025 HIV targets, and the related 2030 Sustainable Development indicator to end AIDS, even if sufficient resources are mobilized.

BackgroundTuberculosis (TB) is the leading cause of infectious disease deaths worldwide and is the leading cause of death among people with HIV. The World Health Organization (WHO) has called for collaboration between public and private healthcare providers to maximize integration of TB/HIV services and minimize costs. We systematically reviewed published models of public-private sector diagnostic and referral services for TB/HIV co-infected patients.MethodsWe searched PubMed, the Cochrane Central Register of Controlled Trials, Google Scholar, Science Direct, CINAHL and Web of Science. We included studies that discussed programs that linked private and public providers for TB/HIV concurrent diagnostic and referral services and used Review Manager (Version 5.3, 2015) for meta-analysis.ResultsWe found 1,218 unduplicated potentially relevant articles and abstracts; three met our eligibility criteria. All three described public-private TB/HIV diagnostic/referral services with varying degrees of integration. In Kenya private practitioners were able to test for both TB and HIV and offer state-subsidized TB medication, but they could not provide state-subsidized antiretroviral therapy (ART) to co-infected patients. In India private practitioners not contractually engaged with the public sector offered TB/HIV services inconsistently and on a subjective basis. Those partnered with the state, however, could test for both TB and HIV and offer state-subsidized medications. In Nigeria some private providers had access to both state-subsidized medications and diagnostic tests; others required patients to pay out-of-pocket for testing and/or treatment. In a meta-analysis of the two quantitative reports, TB patients who sought care in the public sector were almost twice as likely to have been tested for HIV than TB patients who sought care in the private sector (risk ratio [RR] 1.98, 95% confidence interval [CI] 1.88–2.08). However, HIV-infected TB patients who sought care in the public sector were marginally less likely to initiate ART than TB patients who sought care from private providers (RR 0.89, 95% CI 0.78–1.03).ConclusionThese three studies are examples of public-private TB/HIV service delivery and can potentially serve as models for integrated TB/HIV care systems. Successful public-private diagnostic and treatment services can both improve outcomes and decrease costs for patients co-infected with HIV and TB.

Countries worldwide have attempted to reduce the incidence of HIV and AIDS associated deaths with varying success, despite significant progress in antiretroviral treatment (ART) and condom use. A chief obstacles is that key populations affected face high levels of stigma, discrimination and exclusion, limiting the successful response to HIV. However, a gap exists in studies demonstrating the moderation effects of societal enablers on overall programme effectiveness and HIV outcomes using quantitative methods.Structural Equation Modeling was used for 138 countries covering a 12-year period to examine how the unfavorable societal enabling environment, including stigma and discrimination, unfavorable legal environment and lack of access to societal justice, gender inequality and other unfavorable development situations affect the effectiveness of HIV programmes and HIV outcomes, while controlling for potentially confounding variables. The results only showed statistical significance when all four societal enablers were modeled as a composite. The findings show the direct and indirect standardized effects of unfavorable societal enabling environments to AIDS-related mortality among PLHIV are statistically significant and positive (0.26 and 0.08, respectively). We hypothesize that this may be because an unfavorable societal enabling environment can negatively affect adherence to ART, quality of healthcare and health seeking behavior. Higher ranked societal environments increase the effect of ART coverage on AIDS related mortality by about 50% in absolute value, that is -0.61 as against -0.39 for lower ranked societal environments. However, mixed results were obtained on the impact of societal enablers on changes in HIV incidence through condom use. Results indicate that countries with better societal enabling environments had fewer estimated new HIV infections and fewer AIDS-related deaths. The failure to include societal enabling environments in HIV response undermines efforts to achieve the 2025 HIV targets, and the related 2030 Sustainable Development indicator to end AIDS, even if sufficient resources are mobilized.

Among all countries worldwide those in sub-Saharan Africa have the highest rates of HIV. The countries with the highest rates of HIV include Eswatini, South Africa, and Lesotho. In 2024, Eswatini had the highest prevalence of HIV with a rate of around ** percent. Other countries, such as Zimbabwe, have significantly decreased their HIV prevalence. Community-based HIV services are considered crucial to the prevention and treatment of HIV. HIV Worldwide The human immunodeficiency virus (HIV) is a viral infection that is transmitted via exposure to infected semen, blood, vaginal and anal fluids, and breast milk. HIV destroys the human immune system, rendering the host unable to fight off secondary infections. Globally, the number of people living with HIV has generally increased over the past two decades. However, the number of HIV-related deaths has decreased significantly in recent years. Despite being a serious illness that affects millions of people, medication exists that effectively manages the progression of the virus in the body. These medications are called antiretroviral drugs. HIV Treatment Generally, global access to antiretroviral treatment has increased. However, despite being available worldwide, not all adults have access to antiretroviral drugs. There are many different antiretroviral drugs available on the market. As of 2024, ********, an antiretroviral marketed by Gilead, was the leading HIV treatment based on revenue.

According to the findings of a survey by IPSOS, nearly every country in the study overestimates the proportion of deaths resulting from HIV/AIDS or sexually transmitted infections (STIs). A standout exception is South Africa, with an actual 28.8 percent compared to an estimated 10.8 percent of deaths due to HIV/AIDS or STIs. This statistic shows the actual vs public estimates for number of deaths per 100 which occur as a result of HIV/AIDS or STIs, worldwide as of 2019, by country.

Abstract

The 2005 Ethiopia Demographic and Health Survey (2005 EDHS) is part of the worldwide MEASURE DHS project which is funded by the United States Agency for International Development (USAID).

The principal objective of the 2005 Ethiopia Demographic and Health Survey (DHS) is to provide current and reliable data on fertility and family planning behaviour, child mortality, adult and maternal mortality, children’s nutritional status, the utilization of maternal and child health services, knowledge of HIV/AIDS and prevalence of HIV/AIDS and anaemia.

The specific objectives are to: - collect data at the national level which will allow the calculation of key demographic rates; - analyze the direct and indirect factors which determine the level and trends of fertility; - measure the level of contraceptive knowledge and practice of women and men by method, urban-rural residence, and region; - collect high quality data on family health including immunization coverage among children, prevalence and treatment of diarrhoea and other diseases among children under five, and maternity care indicators including antenatal visits and assistance at delivery; - collect data on infant and child mortality and maternal and adult mortality; - obtain data on child feeding practices including breastfeeding and collect anthropometric measures to use in assessing the nutritional status of women and children; - collect data on knowledge and attitudes of women and men about sexually transmitted diseases and HIV/AIDS and evaluate patterns of recent behaviour regarding condom use; - conduct haemoglobin testing on women age 15-49 and children under age five years in a subsample of the households selected for the survey to provide information on the prevalence of anaemia among women in the reproductive ages and young children; - collect samples for anonymous HIV testing from women and men in the reproductive ages to provide information on the prevalence of HIV among the adult population.

This information is essential for informed policy decisions, planning, monitoring, and evaluation of programs on health in general and reproductive health in particular at both the national and regional levels. A long-term objective of the survey is to strengthen the technical capacity of the Central Statistical Agency to plan, conduct, process, and analyse data from complex national population and health surveys. Moreover, the 2005 Ethiopia DHS provides national and regional estimates on population and health that are comparable to data collected in similar surveys in other developing countries. The first ever Demographic and Health Survey (DHS) in Ethiopia was conducted in the year 2000 as part of the worldwide DHS programme. Data from the 2005 Ethiopia DHS survey, the second such survey, add to the vast and growing international database on demographic and health variables.

Wherever possible, the 2005 EDHS data is compared with data from the 2000 EDHS. In addition, where applicable, the 2005 EDHS is compared with the 1990 NFFS, which also sampled women age 15-49. Husbands of currently married women were also covered in this survey. However, for security and other reasons, the NFFS excluded from its coverage Eritrea, Tigray, Asseb, and Ogaden autonomous regions. In addition, fieldwork could not be carried out for Northern Gondar, Southern Gondar, Northern Wello, and Southern Wello due to security reasons. Thus, any comparison between the EDHS and the NFFS has to be interpreted with caution.

Geographic coverage

National

Analysis unit

• Household
• Children under five years
• Women age 15-49
• Men age 15-59

Kind of data

Sample survey data

Sampling procedure

The 2005 EDHS sample was designed to provide estimates for the health and demographic variables of interest for the following domains: Ethiopia as a whole; urban and rural areas of Ethiopia (each as a separate domain); and 11 geographic areas (9 regions and 2 city administrations), namely: Tigray; Affar; Amhara; Oromiya; Somali; Benishangul-Gumuz; Southern Nations, Nationalities and Peoples (SNNP); Gambela; Harari; Addis Ababa and Dire Dawa. In general, a DHS sample is stratified, clustered and selected in two stages. In the 2005 EDHS a representative sample of approximately 14,500 households from 540 clusters was selected. The sample was selected in two stages. In the first stage, 540 clusters (145 urban and 395 rural) were selected from the list of enumeration areas (EA) from the 1994 Population and Housing Census sample frame.

In the census frame, each of the 11 administrative areas is subdivided into zones and each zone into weredas. In addition to these administrative units, each wereda was subdivided into convenient areas called census EAs. Each EA was either totally urban or rural and the EAs were grouped by administrative wereda. Demarcated cartographic maps as well as census household and population data were also available for each census EA. The 1994 Census provided an adequate frame for drawing the sample for the 2005 EDHS. As in the 2000 EDHS, the 2005 EDHS sampled three of seven zones in the Somali Region (namely, Jijiga, Shinile and Liben). In the Affar Region the incomplete frame used in 2000 was improved adding a list of villages not previously included, to improve the region's representativeness in the survey. However, despite efforts to cover the settled population, there may be some bias in the representativeness of the regional estimates for both the Somali and Affar regions, primarily because the census frame excluded some areas in these regions that had a predominantly nomadic population.

The 540 EAs selected for the EDHS are not distributed by region proportionally to the census population. Thus, the sample for the 2005 EDHS must be weighted to produce national estimates. As part of the second stage, a complete household listing was carried out in each selected cluster. The listing operation lasted for three months from November 2004 to January 2005. Between 24 and 32 households from each cluster were then systematically selected for participation in the survey.

Because of the way the sample was designed, the number of cases in some regions appear small since they are weighted to make the regional distribution nationally representative. Throughout this report, numbers in the tables reflect weighted numbers. To ensure statistical reliability, percentages based on 25 to 49 unweighted cases are shown in parentheses and percentages based on fewer than 25 unweighted cases are suppressed.

Note: See detailed sample implementation table in APPENDIX A of the survey report.

Mode of data collection

Face-to-face [f2f]

Research instrument

In order to adapt the standard DHS core questionnaires to the specific socio-cultural settings and needs in Ethiopia, its contents were revised through a technical committee composed of senior and experienced demographers of PHCCO. After the draft questionnaires were prepared in English, copies of the household, women’s and men’s questionnaires were distributed to relevant institutions and individual researchers for comments. A one-day workshop was organized on November 22, 2004 at the Ghion Hotel in Addis Ababa to discuss the contents of the questionnaire. Over 50 participants attended the national workshop and their comments and suggestions collected. Based on these comments, further revisions were made on the contents of the questionnaires. Some additional questions were included at the request of MOH, the Fistula Hospital, and USAID. The questionnaires were finalized in English and translated into the three main local languages: Amharic, Oromiffa and Tigrigna. In addition, the DHS core interviewer’s manual for the Women’s and Men’s Questionnaires, the supervisor’s and editor’s manual, and the HIV and anaemia field manual were modified and translated into Amharic.

The Household Questionnaire was used to list all the usual members and visitors in the selected households. Some basic information was collected on the characteristics of each person listed, including age, sex, education, and relationship to the head of the household. The main purpose of the Household Questionnaire was to identify women and men who were eligible for the individual interview. The Household Questionnaire also collected information on characteristics of the household’s dwelling unit, such as the source of water, type of toilet facilities, materials used for the floor and roof of the house, ownership of various durable goods, and ownership and use of mosquito nets. In addition, this questionnaire was used to record height and weight measurements of women age 15-49 and children under the age of five, households eligible for collection of blood samples, and the respondents’ consent to voluntarily give blood samples.

The Women’s Questionnaire was used to collect information from all women age 15-49 years and covered the following topics. - Household and respondent characteristics - Fertility levels and preferences - Knowledge and use of family planning - Childhood mortality - Maternity care - Childhood illness, treatment, and preventative actions - Anaemia levels among women and children - Breastfeeding practices - Nutritional status of women and young children - Malaria prevention and treatment - Marriage and sexual activity - Awareness and behaviour regarding AIDS and STIs - Harmful traditional practices - Maternal mortality

The Men’s Questionnaire was administered to all men age 15-59 years living in every second household in the sample. The Men’s Questionnaire collected similar information contained in the Women’s Questionnaire, but was shorter because it did not contain questions on reproductive